Eupraxia Pharmaceuticals Company Executives
| EPRX Stock | CAD 7.01 0.14 2.04% |
Eupraxia Pharmaceuticals employs about 33 people. The company is managed by 3 executives with a total tenure of roughly 77 years, averaging almost 25.0 years of service per executive, having 11.0 employees per reported executive. Analysis of Eupraxia Pharmaceuticals' management performance can provide insight into the firm performance.
Eupraxia |
Eupraxia Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.5206) % which means that it has lost $0.5206 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1677) %, meaning that it generated substantial loss on money invested by shareholders. Eupraxia Pharmaceuticals' management efficiency ratios could be used to measure how well Eupraxia Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eupraxia Pharmaceuticals Workforce Comparison
Eupraxia Pharmaceuticals is one of the top stocks in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 99.0. Eupraxia Pharmaceuticals totals roughly 33.0 in number of employees claiming about 33% of equities under Health Care industry.
Eupraxia Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Eupraxia Pharmaceuticals Price Series Summation is a cross summation of Eupraxia Pharmaceuticals price series and its benchmark/peer.
Eupraxia Pharmaceuticals Notable Stakeholders
An Eupraxia Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Eupraxia Pharmaceuticals often face trade-offs trying to please all of them. Eupraxia Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Eupraxia Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
About Eupraxia Pharmaceuticals Management Performance
The success or failure of an entity such as Eupraxia Pharmaceuticals often depends on how effective the management is. Eupraxia Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Eupraxia management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Eupraxia management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada. EUPRAXIA PHARMACEUTICALS operates under Biotechnology classification in Canada and is traded on Toronto Stock Exchange. It employs 19 people.
Eupraxia Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Eupraxia Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Eupraxia Pharmaceuticals within its industry.Eupraxia Pharmaceuticals Manpower Efficiency
Return on Eupraxia Pharmaceuticals Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 780.1K | |
| Net Loss Per Executive | 8.6M | |
| Working Capital Per Employee | 949.5K | |
| Working Capital Per Executive | 10.4M |
Other Information on Investing in Eupraxia Stock
Eupraxia Pharmaceuticals financial ratios help investors to determine whether Eupraxia Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eupraxia with respect to the benefits of owning Eupraxia Pharmaceuticals security.